Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study

  • Caladrius Biosciences Inc (NASDAQ:CLBSsuspended patient enrollment in its Phase 2b FREEDOM Trial of Xowna for coronary microvascular dysfunction (CMD). 
  • As previously communicated, the pandemic impacted the enrollment in the FREEDOM Trial coupled with supply chain issues making enrollment much slower and challenging to accelerate. 
  • The FREEDOM trial enrolled approximately one-third of the targeted 105 patients, and at this rate, more than four years would likely be required to reach the primary endpoint follow-up at 6 months post-treatment for all subjects. 
  • Also Read: Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics.
  • Caladrius believes that this revised timeline is not viable for financial and commercial reasons and requires an alternative development plan.
  • The company intends to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of Xowna in subjects with CMD and corroborate the ESCaPE-CMD study results. 
  • The interim analysis is expected to be completed in August 2022.
  • Price Action: CLBS shares are up 2.17% during the premarket session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.